Tonix Pharmaceuticals Holding Corp. — Director's Dealing 2021

Feb 25, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Tonix Pharmaceuticals Holding Corp. (TNXP)
CIK: 0001430306
Period of Report: 2021-02-23

Reporting Person: SAENGER BRADLEY (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-23	Stock Option	$1.22	A	540000	Acquired	2031-02-23	Common Stock (540000)	Direct
2021-02-23	Stock Option	$1.53	A	540000	Acquired	2031-02-23	Common Stock (540000)	Direct

Footnotes

F1: One-third of the option vests on the first anniversary of issuance and 1/36th each month thereafter for 24 months.

F2: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan.